Micelle delivery of doxorubicin increases cytotoxicity to prostate carcinoma cells.
The use of doxorubicin as a chemotherapeutic agent is hindered by its toxic side effects on the normal cells of the body. The objective of this study was to determine if micelle-delivered doxorubicin could increase the effectiveness of doxorubicin against prostate carcinoma cells. Rat prostate carcinoma cells (MatLu) were cultured under standard conditions. Phosphate-buffered saline (PBS), doxorubicin and/or micelle solution (Pluronic 10500 solution) was added to the cell suspensions and incubated for 3 h. After incubation, cells were washed twice. Analysis consisted of: 1) immediate cell count and 2) proliferation assay at 24 and 144 h. After 24 h, samples with micelle-incorporated doxorubicin had 75% (10% pluronic with 10 microg/ml doxorubicin) and 80% (1% pluronic with 10 microg/ml doxorubicin) cell proliferation results compared with the control group. After 144-h incubation, these same two groups demonstrated cell proliferation results of only 30 and 43% of the control group. The in vitro cytotoxicity of doxorubicin against prostate carcinoma cells was dramatically increased by incorporating the molecule with polymeric micelles.
McNealy
Tamara L
TL
Department of Urology, University Hospital, Mannheim, Germany.
Trojan
Lutz
L
Knoll
Thomas
T
Alken
Peter
P
Michel
Maurice Stephan
MS
D000704:Analysis of Variance; D000818:Animals; D002277:Carcinoma / Q000188:drug therapy; D049109:Cell Proliferation / Q000187:drug effects*; D002470:Cell Survival / Q000187:drug effects; D004317:Doxorubicin / Q000494:pharmacology* / Q000633:toxicity*; D016503:Drug Delivery Systems; D008297:Male; D008823:Micelles; D011336:Probability; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D051381:Rats; D012680:Sensitivity and Specificity; D014407:Tumor Cells, Cultured / Q000187:drug effects
D008823:Micelles; D004317:Doxorubicin